Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

Status:
Recruiting
Trial end date:
2022-12-23
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on elderly male and female study participants with cognitive decline at screening.
Phase:
Phase 1
Details
Lead Sponsor:
Syndesi Therapeutics